Acadia Pharmaceuticals
San Diego, California, United States · Biopharma, Biotechnology, Health Care
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment o
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 501
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (ACAD)
- Website
- acadia.com
- Company page
Recent activity at Acadia Pharmaceuticals
- : Acadia Pharmaceuticals Announces Departure of Elizabeth H.Z. Thompson, Ph.D.
- : SEC 8-K (5.02): On October 23, 2026, Elizabeth H.Z. Thompson, Ph.D., the Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals Inc., officially departed from her position after announcing her retirement on April 27, 2026. While Dr. Thompson will no longer serve as an employee, she will continue to contribute to the Company in a consulting capacity until December 31, 2026. The Company is actively working to find her replacement. This transition marks a significant change in leadership for the Research and Development division, which may influence ongoing and future projects.
- : SEC 8-K (7.01): On September 24, 2026, Acadia Pharmaceuticals Inc. announced the topline results from the Phase 2 portion of its ongoing RADIANT clinical trial program. This trial evaluates the effectiveness of remlifanserin, targeting hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The results are significant as they pave the way for Phase 3 trials, potentially impacting treatment options for ADP. The press release detailing these results is included as an exhibit in the 8-K filing, emphasizing the company's commitment to advancing therapeutic solutions in this area.
- : SEC 8-K (8.01):
- : Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
- : SEC 8-K (5.02): On May 29, 2026, Acadia Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, during which significant corporate governance changes were made. Stockholders approved an amendment to the Company's 2024 Equity Incentive Plan, increasing the share authorization by 5,209,670 shares. Additionally, three nominees were elected as Class I directors to the Board until the 2029 Annual Meeting, including James M. Daly, Edmund P. Harrigan, M.D., and Adora Ndu, Pharm.D., J.D. The meeting also approved executive compensation and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026, reflecting the company's commitment to governance and strategic growth.
- : SEC 8-K (5.02): On April 27, 2026, Dr. Elizabeth H.Z. Thompson, the Head of Research and Development at Acadia Pharmaceuticals Inc., announced her planned retirement for personal reasons. She will continue in her role until a successor is appointed, after which she will serve as a consultant through the end of 2026, including during the review period of a Phase 2 clinical study on remlifanserin for Alzheimer’s disease psychosis. Acadia Pharmaceuticals has started the search for her replacement, indicating a significant change in its leadership structure that may impact ongoing research initiatives and strategic directions.
- : SEC 8-K (5.02): On March 3, 2026, Acadia Pharmaceuticals Inc. appointed Jonathan M. Poole to the Board of Directors to fill a vacancy, effective immediately. Mr. Poole will also serve on the Audit Committee and has an initial term that expires at the Company’s 2027 Annual Meeting of Stockholders. He will receive an annual cash retainer of $50,000 for board service and an additional $12,500 for Audit Committee service, alongside an initial equity award valued at $200,000 under the 2024 Equity Incentive Plan, which will vest over three years. Additionally, he has received a prorated annual grant of equity awards valued at $95,300, with vesting terms that depend on his continued service. This appointment enhances the Board's composition and governance capabilities.
- : SEC 8-K (7.01):
- : SEC 8-K (5.02): On October 30, 2025, Daniel B. Soland resigned from his positions as a member and Chair of the Nominating and Corporate Governance Committee of Acadia Pharmaceuticals Inc.'s Board of Directors. His resignation was communicated to the Board on October 28, 2025, and was effective immediately after. Notably, the resignation was not due to any disagreements with the Company or the Board. This change in board leadership could impact the governance and strategic direction of Acadia Pharmaceuticals going forward.
Leadership
- Elizabeth H.Z. Thompson, Ph.D., Head of Research
- Carl Segerstrom, Chief People Officer
- Konstantina Katcheves, Senior Vice President
- Allyson McMillan-Youngblood, Senior Vice President
- Catherine Owen Adams, Chief Executive Officer
- Elizabeth H. Z. Thompson, Head of Research
- Kimberly J. Manhard, Vice President
- Jennifer J. Rhodes, Vice President
- Kevin Oliver, Chief Business Officer
Verified email and direct lines for Acadia Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Acadia Pharmaceuticals files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Acadia Pharmaceuticals in the news
- Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Yahoo Finance (Sep 24, 2026)
- Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026 - Business Wire (Oct 28, 2026)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD - PR Newswire (Oct 22, 2026)
- Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis - Yahoo Finance (Jul 20, 2026)
- Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma (Mar 03, 2026)
- U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug - Reuters (Aug 04, 2022)
- Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech (Nov 26, 2024)
- Acadia Pharmaceuticals More to Parkinson’s - The Shorty Awards (Feb 21, 2025)
Companies similar to Acadia Pharmaceuticals
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Arcus Biosciences · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Madrigal Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- MacroGenics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Acadia Pharmaceuticals: questions and answers
What does Acadia Pharmaceuticals do?
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment o
Where is Acadia Pharmaceuticals headquartered?
Acadia Pharmaceuticals is headquartered in San Diego, California, United States.
How many employees does Acadia Pharmaceuticals have?
Acadia Pharmaceuticals has about 501 employees.
Who leads Acadia Pharmaceuticals?
Konstantina Katcheves is a Senior Vice President at Acadia Pharmaceuticals.
What is the latest news on Acadia Pharmaceuticals?
On Oct 23, 2026, Acadia Pharmaceuticals Announces Departure of Elizabeth H.Z. Thompson, Ph.D.
Is Acadia Pharmaceuticals a public company?
Yes. Acadia Pharmaceuticals is publicly traded under the ticker ACAD.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy